ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Reports Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates

Acadia Pharmaceuticals Inc. released its second-quarter 2025 financial results, reporting revenue of $264.6 million, a 9% increase year-over-year. While this figure fell slightly short of analyst estimates of $267.1 million, the company’s earnings per share (EPS) of $0.16 surpassed the consensus estimate of $0.14. The market reaction has been muted in after-hours trading, with no significant price movement, though the stock has gained approximately 12.5% over the past month, suggesting some optimism ahead of the earnings release.

Key Financial Highlights

• Revenue: $264.6 million, up 9% YoY, slightly below the $267.1 million estimate.
• EPS: $0.16, beating the $0.14 estimate.
• NUPLAZID Sales: $168.5 million (+7% YoY), driven by volume growth.
• DAYBUE Sales: $96.1 million (+14% YoY), reaching a record 987 unique patients.
• R&D Expenses: $78.0 million, slightly up from $76.2 million in Q2 2024.
• SG&A Expenses: $133.5 million, up from $117.1 million due to commercial team expansion.
• Net Income: $26.7 million, down from $33.4 million in Q2 2024, impacted by a higher tax rate.

Market Reaction and Outlook

Despite the revenue miss, the EPS beat and reaffirmed full-year guidance suggest stable execution. Acadia raised the lower end of its NUPLAZID sales forecast to $665–$690 million (from $650–$690 million) and maintained its total revenue guidance of $1.045–$1.095 billion, aligning closely with analyst expectations of $1.085 billion for 2025.

The lack of significant after-hours movement may reflect a balanced view—while the EPS beat is positive, revenue growth was in line with expectations rather than exceeding them. The stock’s recent upward trend indicates investor confidence in Acadia’s pipeline and commercial execution.

Operational and Pipeline Updates

• R&D Momentum: Acadia highlighted progress across nine programs, with seven Phase 2/3 trials expected to initiate in 2025–2026 and five readouts anticipated by 2027.
• Patent Wins: Secured extended exclusivity for NUPLAZID, with key patents now valid until 2030 and 2038.
• DAYBUE Expansion: Achieved record patient shipments and completed field force expansion to support growth.
• Leadership Additions: Strengthened commercial and data leadership to drive franchise growth and operational efficiency.

Looking Ahead

Analysts project Q3 2025 revenue of $279.7 million, which Acadia’s current trajectory suggests is achievable. The company’s focus on pipeline development—particularly in Prader-Willi syndrome (with ACP-101 Phase 3 data expected in Q4 2025)—could provide additional catalysts.

For more detailed earnings estimates and historical performance, see Acadia’s earnings and estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.